Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are sha** how we study and target Tauopathies
Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …
Involvement of lipids in Alzheimer's disease pathology and potential therapies
H Chew, VA Solomon, AN Fonteh - Frontiers in physiology, 2020 - frontiersin.org
Lipids constitute the bulk of the dry mass of the brain and have been associated with healthy
function as well as the most common pathological conditions of the brain. Demographic …
function as well as the most common pathological conditions of the brain. Demographic …
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …
Tau and neurodegenerative disease: the story so far
In 1975, tau protein was isolated as a microtubule-associated factor from the porcine brain.
In the previous year, a paired helical filament (PHF) protein had been identified in …
In the previous year, a paired helical filament (PHF) protein had been identified in …
Analytical and biochemical perspectives of protein O-GlcNAcylation
Protein O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) is a
unique monosaccharide modification discovered in the early 1980s. With the technological …
unique monosaccharide modification discovered in the early 1980s. With the technological …
[HTML][HTML] Disease-modifying therapies for Alzheimer's disease: more questions than answers
TE Golde - Neurotherapeutics, 2022 - Elsevier
Scientific advances over the last four decades have steadily infused the Alzheimer's disease
(AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune …
(AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune …
Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration
JZ Wang, YY **a, I Grundke-Iqbal… - Journal of Alzheimer's …, 2012 - journals.sagepub.com
Microtubule associated protein tau is a phosphoprotein which potentially has 80
serine/threonine and 5 tyrosine phosphorylation sites. Normal brain tau contains 2-3 moles …
serine/threonine and 5 tyrosine phosphorylation sites. Normal brain tau contains 2-3 moles …
Post-translational modifications of tau protein: implications for Alzheimer's disease
L Martin, X Latypova, F Terro - Neurochemistry international, 2011 - Elsevier
Alzheimer's disease (AD) belongs to a group of neurodegenerative diseases collectively
designated as “tauopathies”, because they are characterized by the aggregation of …
designated as “tauopathies”, because they are characterized by the aggregation of …
Glucose metabolism and AD: evidence for a potential diabetes type 3
A González, C Calfío, M Churruca… - Alzheimer's research & …, 2022 - Springer
Background Alzheimer's disease is the most prevalent cause of dementia in the elderly.
Neuronal death and synaptic dysfunctions are considered the main hallmarks of this …
Neuronal death and synaptic dysfunctions are considered the main hallmarks of this …
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Y Liu, F Liu, I Grundke‐Iqbal, K Iqbal… - The Journal of …, 2011 - Wiley Online Library
Brain glucose metabolism is impaired in Alzheimer's disease (AD), the most common form of
dementia. Type 2 diabetes mellitus (T2DM) is reported to increase the risk for dementia …
dementia. Type 2 diabetes mellitus (T2DM) is reported to increase the risk for dementia …